A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia

George Grossberga Department of Psychiatry & Behavioral Neuroscience, Division of Geriatric Psychiatry, St Louis University School of Medicine, MO, USA

Annette Urganusb Lundbeck LLC, Deerfield, IL, USA

Jeff Scheinc Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, USA

Rebecca Bungayd Analysis Group, Inc, Montréal, QC, CanadaCorrespondence[email protected]

Martin Cloutierd Analysis Group, Inc, Montréal, QC, Canada

Marjolaine Gauthier-Loiselled Analysis Group, Inc, Montréal, QC, Canada

Deborah Chand Analysis Group, Inc, Montréal, QC, Canada

Annie Guerind Analysis Group, Inc, Montréal, QC, Canada

Jyoti Aggarwalc Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, USA

show all

A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date